ZNTL — Zentalis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE- Rocket Lab, Citigroup, Micron
US FDA puts Zentalis' cancer drug studies on partial hold after patient deaths (updated)
U.S. STOCKS ON THE MOVE-Occidental, Mesa Air, Cheniere Energy
Zentalis Pharma falls as FDA puts cancer therapy trials on hold
US FDA puts partial clinical hold on Zentalis' cancer drug studies; shares drop
Brief: Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
Brief: Zentalis Pharmaceuticals On And Effective May 24, Board Increased Its Size From Six To Seven Directors
Zentalis Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Zentalis Pharmaceuticals Q1 Operating Expenses USD 65.325 Million
Zentalis Pharmaceuticals Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Zentalis Pharmaceuticals' CFO Melissa Epperly Resigns, Board Appoints President Cam Gallagher As Interim CFO
Brief: Zentalis Pharmaceuticals Files For Mixed Shelf Size Not Disclosed
Zentalis Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Zentalis Pharmaceuticals Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Immunome Exclusively Licenses Zentalis Ror1 Antibody-Drug Conjugate
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Kenneth Griffin Reports 5.4% Passive Stake In Zentalis Pharmaceuticals As Of Nov 7 - SEC Filing
Brief: Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results And Operational Updates
Brief: Zentalis Pharmaceuticals Q3 EPS USD -0.79